Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Liabilities and Shareholders Equity (2023 - 2025)

Kura Oncology (KURA) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $738.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 2.87% to $738.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 billion, a 21.92% increase, with the full-year FY2025 number at $738.4 million, down 2.87% from a year prior.
  • Liabilities and Shareholders Equity was $738.4 million for Q4 2025 at Kura Oncology, up from $649.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $760.2 million in Q4 2024 to a low of $426.0 million in Q1 2023.
  • A 3-year average of $580.4 million and a median of $534.5 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 69.32% in 2024, then fell 2.87% in 2025.
  • Kura Oncology's Liabilities and Shareholders Equity stood at $448.9 million in 2023, then soared by 69.32% to $760.2 million in 2024, then fell by 2.87% to $738.4 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Liabilities and Shareholders Equity are $738.4 million (Q4 2025), $649.4 million (Q3 2025), and $682.4 million (Q2 2025).